Jamie Spangler | Assistant Professor
John Hopkins University

Jamie Spangler, Assistant Professor, John Hopkins University

Dr. Jamie Spangler earned a Bachelor of Science degree in Biomedical Engineering at Johns Hopkins University and went on to earn a Ph.D. in Biological Engineering at MIT. After completing a postdoctoral fellowship at Stanford University School of Medicine, Dr. Spangler launched her independent research group at Johns Hopkins University in July 2017, jointly between the departments of Biomedical Engineering and Chemical & Biomolecular Engineering. Her lab, located in the Translational Tissue Engineering Center at the School of Medicine, applies structural and mechanistic insights to re-engineer existing proteins and design new proteins that therapeutically modulate the immune response. In particular, her group is interested in engineering immune molecules such as cytokines, growth factors, and antibodies for targeted treatment of diseases such as cancer and autoimmune disorders.

Appearances:



Festival of Biologics Day 1 @ 15:00

Engineered bispecific antibody for targeted inhibition of cancer metastasis

Metastasis is responsible for 90% of all cancer-related deaths, yet current clinical anti-cancer therapies are designed to inhibit or reverse growth of the primary tumor, and fail to address disease spread. Our team discovered a new biochemical pathway involving the interleukin-6 (IL-6) cytokine and the IL-8 chemokine that actively drives tumor cell migration. We further demonstrated that blocking signaling through both the IL-6 and IL-8 receptors significantly decreased tumor cell migration in vitro and also markedly suppressed cancer metastasis in vivo. To translate this finding into a molecular therapeutic approach, we engineered novel bispecific antibodies that simultaneously engage the IL-6 and IL-8 receptors (IL-6R and IL‑8R), introducing an exciting new strategy to specifically target metastasis, independent of tumor growth. Building on this work, we have humanized our bispecific antibody and also generated a panel of antibody topologies to identify the lead candidate for effectively blocking tumor dissemination. This talk will describe the workflow for engineering and evaluating these molecules in order to design safe and effective therapies to treat aggressive malignancies.

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers